Global Biosimilars Partnering Report/Directory 2021: Access Terms and Agreements for 170+ Deals 2010-2021 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Biosimilars Partnering Terms and Agreements 2010 to 2021” report has been added to ResearchAndMarkets.com’s offering.

The Global Biosimilars Partnering Terms and Agreements 2010 to 2021 report provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Biosimilars partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Biosimilars technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual Biosimilars deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

In addition, a comprehensive appendix is provided organized by Biosimilars partnering company A-Z, deal type definitions and Biosimilars partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Biosimilars partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Biosimilars technologies and products.

Report Scope

Global Biosimilars Partnering Terms and Agreements 2010 to 2021 includes:

• Trends in Biosimilars dealmaking in the biopharma industry since 2010
• Access to headline, upfront, milestone and royalty data
• Access to over 170 Biosimilars deal records and contract documents where available
• The leading Biosimilar deals by value since 2010
• Most active Biosimilars dealmakers since 2010
• The leading Biosimilars partnering resources

In Global Biosimilars Partnering Terms and Agreements 2010 to 2021, the available contracts are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy and technology target

Key Topics Covered:

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Biosimilars dealmaking

2.1. Introduction

2.2. Biosimilars partnering over the years

2.3. Most active biosimilars dealmakers

2.4. Biosimilars partnering by deal type

2.5. Biosimilars partnering by therapy area

2.6. Deal terms for biosimilars partnering

2.6.1 Biosimilars partnering headline values

2.6.2 Biosimilars deal upfront payments

2.6.3 Biosimilars deal milestone payments

2.6.4 Biosimilars royalty rates

Chapter 3 – Leading Biosimilars deals

3.1. Introduction

3.2. Top Biosimilars deals by value

Chapter 4 – Most active Biosimilars dealmakers

4.1. Introduction

4.2. Most active Biosimilars dealmakers

4.3. Most active Biosimilars partnering company profiles

Chapter 5 – Biosimilars contracts dealmaking directory

5.1. Introduction

5.2. Biosimilars contracts dealmaking directory

Chapter 6 – Biosimilars dealmaking by technology type

Chapter 7 – Partnering resource center

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

Appendices

Appendix 1 – Biosimilars deals by company A-Z

Appendix 2 – Biosimilars deals by stage of development

Appendix 3 – Biosimilars deals by deal type

Appendix 4 – Biosimilars deals by therapy area

Appendix 5 – Deal type definitions

Companies Mentioned

• BeiGene
• Momenta Pharmaceuticals
• Ewopharma
• Samsung Bioepis
• Compass Biotechnologies
• YL Biologics
• Alvogen
• Simcere Pharmaceuticals
• Medicago
• Cipla
• Merck Serono
• JAMP Pharma Group
• Yoshindo
• SQI Diagnostics
• R-Pharm
• Sandoz
• ProBioGen
• Diabeloop
• Biocnd
• Epirus Biopharmaceuticals
• mAbXience
• AIT Bioscience
• Concord Biosciences
• Abreos Biosciences
• Revance Therapeutics
• Walter and Eliza Hall Institute
• Zhejiang Hisun Pharmaceutical
• TS Dyne
• Amneal Pharmaceuticals
• MGC Diagnostics
• Theradiag
• XL-Protein
• Aceno Biotherapeutics
• Baxter International
• Zhejiang Huahai Pharmaceutical
• BioXpress
• Algorithme Pharma Holdings
• Premier Research
• PharmaPraxis
• GC Pharma
• Univercells
• Synthon
• Chemo Sa Lugano
• Amgen
• Back-A-Line
• Vela Laboratories
• NeuClone
• Cellectis
• TR-Pharm

For more information about this report visit https://www.researchandmarkets.com/r/krrkae

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900